1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

Glooko And T1D Exchange Enter Partnership To Leverage Device Data From Type 1 Diabetics

 
• By Marion Webb

T1D Exchange, a nonprofit research group, will use Glooko’s diabetes data management platform to leverage diabetes device data from thousands of type 1 diabetics and link it with patients’ health records data at participating medical centers. Thanks to the agreement, researchers will gain access to data that can be used to improve patient care and outcomes.

Road Sign to diabetes management - Image

Mountain View, CA-based Glooko, a leader in diabetes management data, and Boston, MA-based T1D Exchange, a nonprofit research group dedicated to improving care for type 1 diabetics, have formed a collaborative agreement to use Glooko's platform to link anonymized diabetes device data from tens of thousands of type 1 diabetes patients with patients' electronic health-care records.

The resulting data sets are intended to give researchers key insights to help improve diabetes patient care and provide better...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

Numerous Injuries Prompt Class I Recall Of Dexcom CGM Receivers

 
• By Brian Bossetta

Dexcom has recalled several models of its glucose monitoring receivers due to a speaker glitch that may suppress vital blood sugar alerts. The FDA designated the recall, which affects thousands of devices, as class I.

US CMS Sets Out Competitive Bidding Rental Model for CGMs; Abbott, Dexcom Could Face Impact

 
• By Shubham Singh

CMS is proposing to classify all CGMs and insulin pumps as “items requiring frequent and substantial servicing” to expand device choice and access for Medicare beneficiaries. Under this framework, CMS also intends to move Class II devices, which include CGMs from Abbott and Dexcom and pumps from Tan

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By Marion Webb

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

No Strings Attached: Big Players Chase Insulet In Fast-Growing Tubeless Insulin Pump Market

 
• By Marion Webb

Medtronic, Tandem and Beta Bionics are gearing up to bring tubeless patch pumps to market, chasing Insulet’s Omnipod 5, the only FDA-cleared patch pump for type 1 and type 2 diabetes. Analysts expect tubeless models to eventually displace durable pumps.

More from Device Area